Cabometyx study ends early after researchers see 'dramatic' benefits in neuroendocrine tumors, Exelixis says

It's not always a good thing when a drug developer stops a cancer trial. But in a recent case for Exelixis, a Cabometyx trial ended early because of an undeniable efficacy showing.

In this study, the company’s Ipsen-partnered tyrosine kinase inhibitor Cabometyx (cabozantinib) was studied in patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors who progressed after prior systemic therapy. In the phase 3 Cabinet trial, the drug showed a “dramatic improvement” compared with placebo in prolonging the time without disease progression or death, the company said.